Characterization of a novel phage against multidrug-resistant Klebsiella pneumoniae

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-14 DOI:10.1007/s00203-024-04106-0

Lili Yang, Chao Wang, Yuan Zeng, Yuqin Song, Gang Zhang, Dawei Wei, Yalin Li, Jie Feng

{"title":"Characterization of a novel phage against multidrug-resistant Klebsiella pneumoniae","authors":"Lili Yang, Chao Wang, Yuan Zeng, Yuqin Song, Gang Zhang, Dawei Wei, Yalin Li, Jie Feng","doi":"10.1007/s00203-024-04106-0","DOIUrl":null,"url":null,"abstract":"<div>Multidrug-resistant Klebsiella pneumoniae (MDR-KP) poses a significant challenge in global healthcare, underscoring the urgency for innovative therapeutic approaches. Phage therapy emerges as a promising strategy amidst rising antibiotic resistance, emphasizing the crucial need to identify and characterize effective phage resources for clinical use. In this study, we introduce a novel lytic phage, RCIP0100, distinguished by its classification into the Chaoyangvirus genus and Fjlabviridae family based on International Committee on Taxonomy of Viruses (ICTV) criteria due to low genetic similarity to known phage families. Our findings demonstrate that RCIP0100 exhibits broad lytic activity against 15 out of 27 tested MDR-KP strains, including diverse profiles such as carbapenem-resistant K. pneumoniae (CR-KP). This positions phage RCIP0100 as a promising candidate for phage therapy. Strains resistant to RCIP0100 also showed increased susceptibility to various antibiotics, implying the potential for synergistic use of RCIP0100 and antibiotics as a strategic countermeasure against MDR-KP.</div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"99","ListUrlMain":"https://link.springer.com/article/10.1007/s00203-024-04106-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Multidrug-resistant Klebsiella pneumoniae (MDR-KP) poses a significant challenge in global healthcare, underscoring the urgency for innovative therapeutic approaches. Phage therapy emerges as a promising strategy amidst rising antibiotic resistance, emphasizing the crucial need to identify and characterize effective phage resources for clinical use. In this study, we introduce a novel lytic phage, RCIP0100, distinguished by its classification into the Chaoyangvirus genus and Fjlabviridae family based on International Committee on Taxonomy of Viruses (ICTV) criteria due to low genetic similarity to known phage families. Our findings demonstrate that RCIP0100 exhibits broad lytic activity against 15 out of 27 tested MDR-KP strains, including diverse profiles such as carbapenem-resistant K. pneumoniae (CR-KP). This positions phage RCIP0100 as a promising candidate for phage therapy. Strains resistant to RCIP0100 also showed increased susceptibility to various antibiotics, implying the potential for synergistic use of RCIP0100 and antibiotics as a strategic countermeasure against MDR-KP.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗耐多药肺炎克雷伯氏菌的新型噬菌体的特征。

耐多药肺炎克雷伯氏菌（MDR-KP）给全球医疗保健带来了巨大挑战，凸显了创新治疗方法的紧迫性。在抗生素耐药性不断上升的情况下，噬菌体疗法成为一种前景广阔的策略，这强调了识别和鉴定临床使用的有效噬菌体资源的迫切需要。在本研究中，我们介绍了一种新型溶解性噬菌体 RCIP0100，根据国际病毒分类委员会（ICTV）的标准，它被归入朝阳病毒属和 Fjlabviridae 科，因为它与已知的噬菌体家族遗传相似性较低。我们的研究结果表明，RCIP0100 对 27 个测试的 MDR-KP 菌株中的 15 个表现出广泛的杀菌活性，包括耐碳青霉烯类的肺炎双球菌（CR-KP）等多种菌株。这使得噬菌体 RCIP0100 成为噬菌体疗法的理想候选药物。对 RCIP0100 产生耐药性的菌株对各种抗生素的敏感性也有所提高，这意味着 RCIP0100 和抗生素有可能协同使用，成为抗击 MDR-KP 的战略对策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊